CompletedPhase 1NCT03020771

Phase I Study to Evaluate Basic Pharmacodynamic, Pharmacological and Toxicological Effects of the Newly Developed Crimean-Congo Hemorrhagic Fever Vaccine for Humans

Studying Crimean-Congo hemorrhagic fever

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
The Scientific and Technological Research Council of Turkey
Principal Investigator
Aydın Erenmemisoglu, MD PhD
TC Erciyes University
Intervention
KIRIM-KONGO-VAX(biological)
Enrollment
60 enrolled
Eligibility
18-55 years · All sexes
Timeline
2014 – 2017

Collaborators

MonitorCRO

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03020771 on ClinicalTrials.gov

Other trials for Crimean-Congo hemorrhagic fever

Additional recruiting or active studies for the same condition.

See all trials for Crimean-Congo hemorrhagic fever →

← Back to all trials